Eris Lifesciences stated that its consolidated net profit increased 12 per cent to Rs 101 crore for the third quarter ended December 2021.
The company stated that the revenue stood at Rs 332 crore in the third quarter of the current fiscal as against Rs 310 crore in the year-ago period, Eris Lifesciences said.
''Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory,'' stated Eris Lifesciences Chairman & Managing Director Amit Bakshi.
(With inputs from PTI)
Jindal Power Withdraws Public Hearing For Gare Pelma Coal Mine After Tamnar Unrest
Mumbai News: No-Parking Restrictions Imposed Near Kurar Election Office For BMC Polls 2025–26
VT-RNT Takes Flight: Air India Express Honours Ratan Tata With Special Aircraft
BMC Elections 2026: Scuffle Erupts As RO Refuses MNS Candidate’s Nomination In Ward 226
